How this works
BPC-157 (Body Protection Compound) is a synthetic pentadecapeptide derived from human gastric juice that has demonstrated cytoprotective, angiogenic, and tissue-repair activity across a wide range of preclinical models. Its regenerative effects appear to operate through several converging pathways: upregulation of vascular endothelial growth factor (VEGF) and endothelial nitric oxide synthase (eNOS) to drive new blood-vessel formation at injury sites; activation of the focal adhesion kinase (FAK)–paxillin signaling cascade, which promotes fibroblast migration and extracellular-matrix remodeling; modulation of the dopaminergic and serotonergic systems, supporting tendon-to-bone and ligament healing; and a robust gastroprotective effect that helps preserve mucosal integrity under stress. TB-500 is a synthetic fragment of thymosin beta-4 (TB4), a naturally occurring 43-amino-acid actin-sequestering protein. TB4's primary mechanism is its ability to bind and sequester G-actin, liberating monomers to drive actin polymerization at the leading edge of migrating cells — a process essential for keratinocyte and endothelial cell movement during wound closure. Beyond actin regulation, TB-500 is reported to upregulate actin and promote cell migration and differentiation, modulate inflammatory cytokine responses, and support cardiac and skeletal muscle repair following ischemic or mechanical injury. When combined as a 1:1 blend, the two peptides are thought to act on complementary but non-overlapping repair pathways: BPC-157 stimulates the local vascular and matrix-remodeling environment at the injury site, while TB-500 supports systemic cell migration and broader soft-tissue regeneration. This complementary action is the rationale for the popular 'wolverine' research stack, which aims to accelerate tendon, ligament, muscle, and connective-tissue recovery in animal and in-vitro models. Both compounds remain unapproved for human use outside clinical trials, and published evidence is predominantly preclinical.